Weekly Research Analysts’ Ratings Changes for Charles River Laboratories International (CRL)

Several brokerages have updated their recommendations and price targets on shares of Charles River Laboratories International (NYSE: CRL) in the last few weeks:

• 11/17/2025 – Charles River Laboratories International was given a new $200.00 price target on by analysts at Argus.
• 11/17/2025 – Charles River Laboratories International was upgraded by analysts at Argus from a “hold” rating to a “buy” rating.
• 11/11/2025 – Charles River Laboratories International had its price target raised by analysts at Morgan Stanley from $170.00 to $185.00. They now have an “equal weight” rating on the stock.
• 11/10/2025 – Charles River Laboratories International had its price target lowered by analysts at TD Cowen from $205.00 to $197.00. They now have a “buy” rating on the stock.
• 11/8/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/6/2025 – Charles River Laboratories International was upgraded by analysts at Baird R W from a “hold” rating to a “strong-buy” rating.
• 11/6/2025 – Charles River Laboratories International had its price target raised by analysts at JPMorgan Chase & Co. from $160.00 to $165.00. They now have a “neutral” rating on the stock.
• 11/6/2025 – Charles River Laboratories International had its price target raised by analysts at Barclays PLC from $195.00 to $210.00. They now have an “overweight” rating on the stock.
• 11/6/2025 – Charles River Laboratories International was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $199.00 price target on the stock, up previously from $178.00.
• 10/23/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 10/17/2025 – Charles River Laboratories International had its price target raised by analysts at Mizuho from $155.00 to $174.00. They now have a “neutral” rating on the stock.
• 10/15/2025 – Charles River Laboratories International was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 10/8/2025 – Charles River Laboratories International had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 10/6/2025 – Charles River Laboratories International was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.
• 10/3/2025 – Charles River Laboratories International had its price target raised by analysts at Evercore ISI from $190.00 to $200.00. They now have an “outperform” rating on the stock.
• 10/2/2025 – Charles River Laboratories International was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating. They now have a $195.00 price target on the stock, up previously from $165.00.
• 9/29/2025 – Charles River Laboratories International was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 9/27/2025 – Charles River Laboratories International had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 9/21/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).